Idryx

IDRX is a clinical-stage biopharmaceutical company focused on developing next-generation precision medicines for cancer, specifically targeting gastrointestinal stromal tumors (GIST). The company was founded by industry veterans to address the high unmet need in GIST patients who develop resistance to existing KIT inhibitors. IDRX's lead program, IDRX-42, is a highly selective small molecule inhibitor designed to target both primary and secondary KIT mutations. The company is also advancing IDRX-73, another potent KIT inhibitor, as part of its strategy to provide best-in-class treatment options. Backed by a $122 million Series A financing, IDRX is leveraging its deep expertise in kinase biology to build a robust pipeline of targeted oncology therapies.